Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
875 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
21 Recruiting High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Icotinib
22 Recruiting Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Condition: Progression Free Survival
Interventions: Drug: Osimertinib;   Drug: docetaxel, bevacizumab
23 Recruiting Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Glesatinib;   Drug: Sitravatinib;   Drug: Mocetinostat;   Drug: Nivolumab
24 Not yet recruiting A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Conditions: Non-small Cell Lung Cancer;   Renal Cell Cancer;   Breast Cancer;   Bladder Cancer;   Head and Neck Cancer;   Colorectal Cancer
Intervention: Drug: SGN-2FF
25 Not yet recruiting Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Cisplatin;   Radiation: hypofractionated radiotherapy;   Drug: Pemetrexed;   Drug: Etoposide
26 Recruiting Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
Condition: Malignant Pleural Effusion
Intervention: Drug: Bevacizumab
27 Not yet recruiting Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance
Condition: Non-small-cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: pemetrexed or gemcitabine plus carboplatin,;   Drug: bevacizumab
28 Not yet recruiting Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC
Condition: Non-small Cell Lung Cancer
Intervention: Drug: BPI-9016M
29 Recruiting Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
Condition: Non-Small Cell Lung Carcinoma
Interventions: Drug: BGB324;   Drug: Docetaxel
30 Not yet recruiting Detection of Circulating Biomarkers of Immunogenic Cell Death
Condition: Non Small Cell Lung Cancer
Intervention: Other: Blood withdrawal
31 Not yet recruiting Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Gedatolisib;   Drug: Paclitaxel;   Drug: Carboplatin
32 Not yet recruiting Effect of Different Anesthetics on the Change of Alarmins in Lung Cancer Patients Receiving Pulmonary Lobectomy
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Sevoflurane;   Drug: Propofol
33 Not yet recruiting Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Fexofenadine tablet dosing;   Drug: Osimertininb tablet dosing
34 Recruiting Arginase Inhibitor CB-1158 in Patients With Solid Tumors
Conditions: Metastatic Cancer;   Solid Tumors;   Non-small Cell Lung Cancer;   Colo-Rectal Cancer;   Gastric Cancer;   Renal Cell Carcinoma;   Squamous-cell Carcinomas of the Head and Neck
Interventions: Drug: CB-1158;   Drug: Nivolumab
35 Recruiting A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Conditions: Colorectal Cancer;   Triple Negative Breast Cancer;   Non-small Cell Lung Cancer (Adenocarcinoma)
Interventions: Biological: PDR001;   Biological: ACZ885;   Biological: CJM112;   Drug: TMT212;   Drug: EGF816
36 Not yet recruiting Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
Condition: Small Cell Lung Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Cisplatin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
37 Not yet recruiting Microwave Ablation in the Treatment of Stage I Non Small Cell Lung Cancer
Condition: Stage I NSCLC
Intervention: Other: microwave ablation
38 Recruiting Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)
Condition: Stage IV EGFR Mutated Non-Small Cell Lung Cancer
Interventions: Radiation: Radiation: SBRT;   Drug: TKI (Gefitinib or Tarceva )
39 Recruiting A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors
Conditions: Hepatocellular Carcinoma;   Renal Cell Carcinoma;   Bladder Cancer;   Colorectal Cancer;   Non-small-cell Lung Cancer;   Breast Cancer
Intervention: Biological: D-CIK and anti-PD-1 antibody
40 Not yet recruiting SIMT Stereotactic Radiosurgery Outcomes Study
Conditions: Brain Metastases;   Breast Cancer;   Non Small Cell Lung Cancer;   Gastrointestinal Cancer;   Renal Cell Cancer;   Melanoma
Intervention: Radiation: Stereotactic radiosurgery

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.